Oncology Drugs

Mispro's new contract vivarium at Genesis Science Center aims to provide crucial, flexible lab space for San Diego's burgeoning biotech startups.

Led by OrbiMed, the financing will propel Accro's promising oral RIPK2 inhibitor for Ulcerative Colitis into a pivotal Phase IIb clinical trial.

Ozari Health launches a nationwide service for affordable compounded semaglutide, navigating a complex and increasingly regulated market for GLP-1 drugs.

Strong glaucoma sales and disciplined spending helped Iridex narrow its quarterly loss, signaling resilience despite retina segment woes and global headwinds.

Renowned cancer researcher Dr. Dario Altieri leaves a top CEO post to return to the lab at Jefferson, signaling a major shift in Philadelphia's science scene.

Amplexd Therapeutics launches a Phase 2 trial in Hong Kong for a novel, non-surgical HPV therapy, offering hope to millions in diagnostic limbo.

With a new $17.5M financing, Forlong Biotechnology accelerates its promising IL-15 and IL-18 cancer drugs, aiming to redefine post-PD-1 immunotherapy.

A top scientific honor for Dr. Mariano Garcia-Blanco validates a new approach to autoimmune disease, targeting a genetic trait in 50% of the population.

A $290M war chest fuels a new public biotech aiming to help millions of migraine patients who don't respond to current blockbuster therapies.

Rancho BioSciences' new OmicsHQ platform offers analysis-ready datasets, aiming to eliminate data cleanup and accelerate AI-driven drug discovery.

Mestag Therapeutics begins a human trial for MST-0312, a novel antibody designed to force tumors to build their own immune-boosting structures.

Mineralys Therapeutics' lorundrostat shows promise for millions with uncontrolled blood pressure and kidney disease, targeting a key hormonal driver.

A $200,000 donation, part of a $1M commitment, funds vital cancer research and celebrates one young girl's triumphant journey to recovery.

Biotheryx's novel protein degrader, BTX-9341, shows impressive safety and efficacy in patients who have progressed on standard therapies.

A new bispecific antibody, TRIV-573, enters clinical trials, targeting both skin barrier and inflammation to redefine atopic dermatitis therapy.

A new oral drug for depression shows rapid, robust effects in a key trial, offering hope for millions by targeting a different brain pathway.

NFL legend Brett Favre reports gains from an experimental Parkinson's drug, but what does the science say about this potential breakthrough treatment?

A new alliance aims to develop first-in-class drugs for Alzheimer's and Parkinson's by targeting chronic brain inflammation, a key driver of disease.

A new drug targeting the root cause of sebum production shows promise in clinical trials, offering hope for millions of moderate to severe acne sufferers.

Actuate Therapeutics gets FDA nod for its oral cancer drug elraglusib, shifting strategy to improve patient outcomes and tackle hard-to-treat tumors.